News | Ventricular Assist Devices (VAD) | September 18, 2015

SynCardia Systems Issues Class I Recall of Freedom Driver System

Part failure on drive mechanism for Total Artificial Heart could cause device to stop pumping, resulting in serious injury or death

Freedom Driver, SynCardia, recall, Total Artificial Heart, TAH-t, part failure

Freedom Driver attached to Total Artificial Heart. Image courtesy of SynCardia.

September 18, 2015 — SynCardia Systems initiated a Class I recall of the Freedom Driver Systems used with the company’s temporary Total Artificial Heart (TAH-t) on Aug. 6, 2015. The recall focused on a specific part of the Freedom Driver drive mechanism that the company said may fail and cause the device to stop pumping.

The SynCardia TAH-t is a mechanical replacement for a patient’s heart, used in patients at risk of imminent death from heart failure who are waiting for a heart transplant. It is a pump that is implanted into the chest to replace the bottom half of a patient’s heart (left and right ventricles). The device is sewn to the remaining top half of the patient’s heart (atria). The Freedom Driver system is attached to the TAH-t pump and operates and monitors the device.

SynCardia noted that patients do not receive any advance warning that the device may fail. If it does fail, a red light located in the center of the driver, toward the top, will stay red and a loud continuous alarm will sound.

However, if the Freedom Driver stops pumping, the patient will lose consciousness almost immediately, which means that the warning light and alarm may not be helpful. The patient will likely experience serious injury or death if not immediately switched to a backup driver by a caregiver.

In the Urgent Medical Device Recall Letter, SynCardia told customers they would notify all hospitals that have the affected drivers — in lot numbers 85978 (serial numbers 85978-001 through 85978-040) and 85979 (Serial Numbers 85979-001 through 85979-040) — and replace the drivers with new ones. Additionally, SynCardia informed customers to:

  • Notify any patients with an affected device and exchange the driver;
  • A SynCardia representative will assist with replacement and return of the product; and
  • Return affected Freedom Drivers and complete the Recall Acknowledgement and Receipt Form attached to the letter.

For more information: www.fda.gov/medwatch

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init